Candida auris: clinical profile, diagnostic challenge, and susceptibility pattern- an experience from a tertiary care centre in South India.
Candida auris is an emerging, multidrug-resistant yeast transmitted in healthcare settings. Conventional methods of speciation are unable to identify C.auris up to species level. Three methods namely Vitek MS v 3.0, Vitek 2 and target sequencing of the internal transcribed spacer(ITS) and 28srRNA genes were evaluated. Antifungal susceptibility testing (AFST) and risk factors of acquiring C.auris candidemia were also studied. Between November 2016 and November 2017, 203 isolates of Candida spp were isolated from blood cultures, of which 11 isolates unidentifiable by conventional methods were further tested by Vitek MS version 3.0, Vitek 2 and confirmed by sequencing. Antifungal susceptibility testing was carried out on all isolates by microbroth dilution as per CLSI guidelines. The clinical and epidemiological data of all patients were reviewed from the electronic patient records. Of the 11 isolates identified as C.auris by both ITS and 28SrRNA sequencing, Vitek 2 identified only 5 as C.auris and Vitek MS v3.0 was not able to identify any of them as C.auris. Ten (90%) isolates were resistant to fluconazole, and all isolates were susceptible to amphotericin B and caspofungin. C.auris can be misidentified in routine microbiology laboratories and sequencing remains the gold standard if commercial identification systems are not updated.